Navigation Links
St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
Date:8/29/2007

Results of a study by investigators at St. Jude Childrens Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted therapy drugs are designed to block the activity of a specific molecule, a strategy aimed at making treatments more effective and less toxic.

The findings may shed new light on why a small percentage of children with ALL do not benefit from treatment, while more than 90 percent of children treated with the latest therapies survive. The discovery could also help researchers better understand both the origins of this form of aggressive ALL as well as why it becomes resistant to imatinib; and this knowledge may lead to more effective treatments for patients who are not helped by current therapies.

CML and an aggressive form of ALL share the same critical mutationthe Philadelphia chromosome (Ph). Cells that have this mutation (Ph+ cells) produce a rogue growth-promoting enzyme called BCR-ABL. Now, work by a team headed by Charles J. Sherr, M.D., Ph.D., a Howard Hughes Medical Institute investigator and co-chair of the St. Jude Department of Genetics and Tumor Cell Biology, has shown that these two forms of leukemia part company in a crucial respect.

Many Ph+ ALL cells lack a tumor-suppressor gene called Arf, which is normally present in CML cells at the time the disease is first diagnosed, said Sherr. Stripped of the anti-tumor effects of Arf and nurtured by growth factors produced in the bone marrow, these ALL cells become less responsive to imatinib and more difficult to eliminate. Sherr reasons that the cells survival advantage increases their opportunity to develop mutations in the BCR-ABL protein, which prompt imatinib resistance.

A report on these results appears in the Septe
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Current human embryonic stem cell lines contaminated UCSD/Salk team finds
2. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
3. Study finds more than one-third of human genome regulated by RNA
4. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
5. Same mutation aided evolution in many fish species, Stanford study finds
6. NC State scientist finds soft tissue in T. rex bones
7. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
8. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
9. Genetically modified rice in China benefits farmers health, study finds
10. Survey finds silver contamination in North Pacific waters
11. Anti cancer virotherapy well tolerated in first human administration, research finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... sequencing technologies continue to evolve rapidly, becoming part of ... appropriate policies and regulatory frameworks to address potential challenges, ... issue of the Journal of Law, Medicine & ... with the Center for Medical Ethics and Health Policy ... tools to jumpstart this process. , Experts with ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... an Israeli start-up company, launched its first "solar farm" near ... systems developed by Prof. David Faiman of Ben-Gurion University ... Faiman, who is chairman of the Department of ... for Desert Research, believes the new system will harvest more ...
... for the 61st Annual Meeting of the Rocky Mountain ... 11-13 May 2009 in Orem, Utah. Utah Valley ... library building on the UVU campus. Brigham Young University ... and industry scientists, and graduate and undergraduate students, will ...
... Ill. Researchers at the University of Illinois have ... one or more molecules into the cytoplasm or the ... amounts of cargo, the nanoneedle can also be used ... "Nanoneedle-based delivery is a powerful new tool for studying ...
Cached Biology News:Ben-Gurion University research and technology used in new solar energy farm 2Geoscientists meet to discuss Rocky Mountain geology 2Nanoneedle is small in size, but huge in applications 2
(Date:9/23/2014)... 23, 2014 Erlab , the ... since 1968 and Burdinola, supplier of laboratory furniture solutions, ... filtered fume hood. , By integrating ... Burdinola will now offer an innovative solution utilizing the ... of chemicals, best-in-class detection technology, and communication for security ...
(Date:9/23/2014)... 23, 2014 For the fifth time since ... list of the fastest-growing companies. , “We’re so proud ... again by Inc. Magazine,” ExakTime CEO Tony Pappas said. , ... posting a three-year growth rate of 61 percent from 2010 ... by more than 40 percent. , Pappas cited strong performance ...
(Date:9/23/2014)... 23, 2014  Age Defying Dermatology ® , owned ... become one of the first clinics in the Bay ... laser for tattoo removal. The treatment safely and effectively ... years, tattoo removal has been a lengthy, painful, and ... is an opportunity to erase tattoo pigment more efficiently ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart Data ... the recent ‘Hype Cycle for Life Sciences 2014 ’ ... key insights pertaining to the benefits in the knowledge ... Shanler and Stephen Davies, “The use of these systems ... scientific stakeholders, and support collaboration and innovation strategies as ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2
... Aug. 20 Vical Incorporated,(Nasdaq: VICL ) ... with,the appointment of Andrew R. de Guttadauro as ... Mr. de Guttadauro was Senior Director of,Strategy at ... overseeing the commercial development of that company,s Zevalin,the ...
... with Sales Team Forming and Increased Space, Poised for ... Medical Technologies,Inc., which is developing innovative devices for the ... a VP of Sales, Joseph W.,Rafferty, and has started ... its first product, Pathway PV(TM) Atherectomy System. Recently ...
... and CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... the second quarter of 2007 increased more than,35% over ... 139 times,revenues of just $13,351 for the same period ... half of 2007 were $3,256,000 compared to only,$24,374 in ...
Cached Biology Technology:Vical Names Andrew de Guttadauro Vice President, Corporate Development 2Vical Names Andrew de Guttadauro Vice President, Corporate Development 3Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
... is available in a ready-to-use format. ... for dewaxing paraffin-embedded tissue sections prior ... or other analytical methods. The conventional ... dipping the slides in a series ...
... The BioGenex Super ... System is a novel ... proprietary non-biotin polymeric technology. ... high signal to noise ...
... thermal cycler is a compact instrument for gene ... tubes, 12 x 0.5 ml tubes, or a ... a thumbwheel to adjust height and pressure to ... heat pumps provide excellent thermal performance, and the ...
Biology Products: